GE HealthCare M&A: The company is in talks to buy radiopharma firm Sophie Biosciences for about $1B, signaling continued push into imaging and theranostics. Sanctions & supply chains: Russia struck multiple Ukrainian medicines warehouses in September, raising fresh concerns about access to Western pharma products. Infectious disease controls: Russia tightened border sanitary checks over Ebola risk, with symptomatic arrivals to be hospitalized. Healthcare policy debate: A US online backlash is growing around calls for “Medicare for All,” with voters questioning affordability and cost estimates. Mental health & work: New research links remote work plus living alone to higher social isolation and worse mental health. Clinical pipeline updates: Cyllene Therapeutics won FDA RMAT designation for EG110A in neurogenic detrusor overactivity, while Pharmazz secured orphan drug status for sovateltide in neonatal hypoxic-ischemic encephalopathy. Obesity drug data: Corbus reported positive topline Phase 1b results for oral CRB-913, including ~5% mean weight loss at 60 mg by 12 weeks. Access & expansion: Soleo Health opened new Atlanta-area infusion centers in Woodstock and Fayetteville to bring alternate-site care closer to patients. Quality & recalls: Zimbabwe’s medicines regulator ordered a Class II recall of three Remedica products after out-of-specification stability results. Primary care pressure: Nigeria’s primary healthcare centres are widely reported as non-functional and understaffed, fueling calls for urgent fixes.